Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Lewis Titterton, Jr. Acquires 49,036 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. acquired 49,036 shares of Anixa Biosciences stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average cost of $2.69 per share, for a total transaction of $131,906.84. Following the completion of the purchase, the director directly owned 1,046,003 shares in the company, valued at approximately $2,813,748.07. This represents a 4.92% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX traded down $0.08 during trading on Friday, reaching $2.70. 179,907 shares of the stock were exchanged, compared to its average volume of 204,111. The firm’s 50-day moving average price is $3.25 and its 200 day moving average price is $2.97. The firm has a market cap of $93.85 million, a price-to-earnings ratio of -8.44 and a beta of 0.51. Anixa Biosciences Inc has a 12-month low of $2.32 and a 12-month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). As a group, equities research analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ANIX. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. HC Wainwright lowered their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Weiss Ratings raised shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Anixa Biosciences presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently added to or reduced their stakes in ANIX. Renaissance Technologies LLC grew its position in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after acquiring an additional 7,300 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in Anixa Biosciences in the 2nd quarter valued at about $29,000. Northwestern Mutual Wealth Management Co. acquired a new position in Anixa Biosciences during the 2nd quarter valued at about $29,000. Integrated Wealth Concepts LLC acquired a new position in Anixa Biosciences during the 2nd quarter valued at about $30,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $34,000. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.